Wilkes Ryan, Tasker Robert C
1Division of Critical Care, Department of Anesthesia, Pain and Perioperative Medicine, Boston Children's Hospital, Boston, MA. 2Department of Neurology, Boston Children's Hospital, Boston, MA.
Pediatr Crit Care Med. 2014 Sep;15(7):632-9. doi: 10.1097/PCC.0000000000000173.
A systematic literature search and review of the best evidence for intensive care treatment of refractory status epilepticus in children using continuous infusion of midazolam or anesthetic agents.
MEDLINE and EMBASE search before December 2013 using key words and/or Medical Subject Headings identified English-language citations that were screened for eligibility and used if 1) the study was about high-dose benzodiazepine or anesthetic agent for children; 2) the treatment protocol was described and used for refractory status epilepticus; 3) the outcomes included seizure control; and 4) the series included at least five children.
Sixteen studies (645 patients) were identified, including midazolam (nine studies), barbiturate (four studies), and other anesthetic approaches (three studies). When midazolam was used as the initial agent for refractory status epilepticus, the rate of clinical seizure control was 76%, which was achieved on average 41 minutes after starting the infusion. When midazolam was used in conjunction with continuous electroencephalography, the time to seizure control was much longer and the mean dose required for seizure control was 10.7 μg/kg/min compared with a lower dose (2.8 μg/kg/min) in the studies not using this form of monitoring, suggesting that continuous electroencephalography provided additional targets for treatment. Barbiturates were usually used after midazolam failed and treatment was started, on average, 66 hours after refractory status epilepticus onset with the goal of electroencephalography burst suppression, which was achieved, on average, 22.6 hours later. Among patients failing midazolam, barbiturate infusion was effective in 65%. Inhaled anesthetics, ketamine, and hypothermia were generally used after prior therapy with midazolam and barbiturates had failed, usually several days after seizure onset.
The data on intensive care treatment of pediatric refractory status epilepticus are of poor quality, yet they show a hierarchy in strategies: early midazolam, then barbiturates, and then trial of other anesthetic strategies. In addition, using a solely clinical endpoint for seizure control may be missing significant seizure burden in pediatric refractory status epilepticus.
对使用咪达唑仑持续输注或麻醉剂对儿童难治性癫痫持续状态进行重症监护治疗的最佳证据进行系统的文献检索和综述。
2013年12月前在MEDLINE和EMBASE数据库进行检索,使用关键词和/或医学主题词筛选出英文文献,若符合以下条件则纳入研究:1)该研究是关于儿童高剂量苯二氮䓬类药物或麻醉剂;2)描述了治疗方案并用于难治性癫痫持续状态;3)结局包括癫痫发作控制;4)该系列研究至少纳入五名儿童。
共纳入16项研究(645例患者),包括咪达唑仑(9项研究)、巴比妥类药物(4项研究)和其他麻醉方法(3项研究)。当咪达唑仑用作难治性癫痫持续状态的初始药物时,临床癫痫发作控制率为76%,平均在开始输注后41分钟实现。当咪达唑仑与持续脑电图监测联合使用时,癫痫发作控制时间长得多,癫痫发作控制所需的平均剂量为10.7μg/kg/min,而在未使用这种监测形式的研究中较低剂量为2.8μg/kg/min,这表明持续脑电图监测为治疗提供了额外靶点。巴比妥类药物通常在咪达唑仑治疗失败后使用,平均在难治性癫痫持续状态发作66小时后开始治疗,目标是实现脑电图爆发抑制,平均在22.6小时后实现。在咪达唑仑治疗失败的患者中,巴比妥类药物输注在65%的患者中有效。吸入麻醉剂、氯胺酮和低温疗法通常在咪达唑仑和巴比妥类药物先前治疗失败后使用,通常在癫痫发作数天后。
儿童难治性癫痫持续状态重症监护治疗的数据质量较差,但显示出策略上的层次:早期使用咪达唑仑,然后是巴比妥类药物,然后尝试其他麻醉策略。此外,仅使用临床终点来控制癫痫发作可能会遗漏儿童难治性癫痫持续状态中显著的癫痫发作负担。